#3Dbioprinting #3dprintedskin #biotechnology #organtransplant #nextbiginnovationlab #nbil #innovationlab #trivima #innoskin #futureoforgantransplant
Can you imagine zero wait times for an organ transplant? This may soon be possible, thanks to the work being done by the pioneering biotech company, Next Big Innovation Labs. It is making exceptional use of disruptive 3D Bioprinting technology to revolutionize pharmaceutical, clinical and cosmetic Research and Development.

Piyush Padmanabhan is the Co-Ceo/Co-Founder at the Next Big Innovations Labs a startup of enthusiastic individuals on a mission to confront the world's most challenging problems in the healthcare space.NBIL is a research-driven startup working on a novel approach to tackle the current muddle vexing the pharmaceutical, clinical and cosmetic R&D sectors. NBIL focusses on solving the organ availability crisis plaguing the entire globe using 3D Bioprinting; aiming to create a world where the abyss between organ demand and availability for organ transplantation is bridged by in-vitro organogenesis.

NBIL’s proprietary printer, Trivima, India’s first customisable 3D Bioprinter is set to transform many traditional areas of medical research and practice, like bone regeneration, wound healing and new material development.
Innoskin is NBIL's 3D Bioprinted Human skin, complete with the intricate architecture, that is developed using patient’s own cells to treat wounds, burns and other skin related injuries and cosmetic corrections.
Next Big Learning is their foundation course on 3D bioprinting

[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

свернуть